Cilta-Cel in the Multiple Myeloma Treatment Landscape: Thomas G. Martin, MD
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.
Around the Helix: Gene and Cell Therapy Company Updates - January 26, 2022
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.
Expanding Study Populations of Cell Therapy in Sickle Cell Disease: Michael Grimley, MD
The medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.
TCR T-Cell Therapy to be Evaluated in Advanced Esophageal or EGJ Cancers
The SURPASS-2 trial will run parallel to the ongoing SURPASS trial.
Challenges of Cell Therapy in Solid Tumors: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.
Stem Cell Gene Therapy Efficacious in Metachromatic Leukodystrophy
Investigators from IRCCS San Raffaele analyzed results from a phase 1/2 study on atidarsagene autotemcel.
Selecting Targets in Hematologic Malignancies
Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed MDG1011 and Medigene’s future research and targets.
HLA LOH Prevalent in GI Cancers, Identifies Future Study Participants
The BASECAMP-1 study is identifying patients for future use of Tmod CAR T-cell therapies.
T-Cell Therapy Gets Orphan Drug Designation for Pancreatic Cancer
The T-cell therapy targets 6 tumor-associated antigens that are highly expressed in pancreatic cancer.
Evaluating MB-106 in B-NH Lymphoma and CL Leukemia: Mazyar Shadman, MD
The associate professor from Fred Hutchinson Cancer Research Center discussed the methods utilized in an ongoing phase 1/2 trial evaluating MB-106.
DLBC Lymphoma CAR T Therapy Granted RMAT and Fast Track Designations
Positive data from a phase 1 trial were presented at the 2021 ASCO meeting.
Improving Outcomes in Hemophilia With Fitusiran: Guy Young, MD
The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic.
GeneTherapyLive’s Weekly Rewind – January 21, 2022
Review top news and interview highlights from the week ending January 21, 2022.
Omidubicel BLA Submission for Hematologic Malignancies Expected First Half of 2022
The FDA and Gamida Cell have reached a consensus on the comparability of omidubicel manufactured at different sites.
Novel Chemo/NK Cell Therapy Combination Shows Efficacy in Pancreatic Cancer
Data from the phase 2 QUILT-88 study were presented at the 2022 ASCO GI symposium.
First In-Human Study Initiated for CAR Macrophage Cell Therapy for Solid Tumors
Carisma Therapeutics and Moderna are also collaborating to develop CAR-M cell therapies.
First Patient Dosed in CAR T-Cell Therapy/Pembrolizumab Trial for Colorectal Cancer
Further details on the KEYNOTE-B79 trial were presented at the 2022 ASCO GI Symposium.
Improving Outcomes in Corneal Endothelial Disease With Cell Therapy
Greg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.
Around the Helix: Gene and Cell Therapy Company Updates - January 19, 2022
Trial Initiated for Pediatric Liver Cancer Cell Therapy
The phase 1/2 ARYA-2 trial will be run in parallel with the similar phase 1/2 ARYA-1 and ARYA-3 trials.
Cilta-Cel's Efficacy in Heavily Pretreated Patients With Multiple Myeloma: Thomas G. Martin, MD
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.
FDA Extends BLA Review for bluebird bio’s β-Thalassemia and CALD Gene Therapies
Eli-cel remains on clinical hold in cerebral adrenoleukodystrophy after a report of persistent anemia.
Celularity’s CYNK-101 Wins Fast Track Designation for HER2+ Gastric/GEJ Cancers
The designation follows the approval of its IND application for the natural killer cell therapy in November 2021.
Fabry Disease Gene Therapy Shows Efficacy in First 2 Patients
The first patient with Fabry disease dosed with FLT190 2 years ago continues to have elevated, sustained α-Gal A.
Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.
Second Pivotal Trial Initiated for Wet AMD Gene Therapy
The ASCENT trial is kicking off while the ATMOSPHERE trial continues to screen patients with wet AMD.
Increasing CAR T-cell Use in R/R DLBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD
Experts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.
Liso-Cel's Efficacy in R/R Large B-Cell Lymphoma: Michael Wang, MD
The professor from University of Texas MD Anderson Cancer Center discussed the FDA approval of lisocabtagene maraleucel.
Improving Outcomes in Solid Tumors With Personalized Cell Therapies
Cedrik Britten, MD, chief medical officer, Immatics, discussed the advantages of IMA203 over other cell therapies.
Sickle Cell Disease Cell Therapy Clinical Trial Enrolls First Patient
Details on the phase 1/2 CEDAR trial were presented at the 2021 ASH meeting.